Infectious Vaccines Market Size, Share & Trends Analysis Report By Application, Regional Outlook, Competitive Strategies, And Segment Forecasts, 2019 To 2025

The global Infectious vaccines market is expected to witness a growth of over 12% CAGR over the forecast period owing to the growing prevalence of chronic diseases such as HIV, cancer, diabetes, and Alzheimer's. Rising consumer awareness regarding health coupled with rising disposable income is expected to propel the demand for infectious vaccines over the next seven years. Furthermore, increasing government activities to control epidemic diseases such as polio, camp fever, and swine flu is projected to have an impact on market growth significantly over the next seven years. Growing awareness regarding harmful effects, symptoms, and causes coupled with easy accessibility of drugs is likely to drive the market growth.

Rising investment by pharmaceutical companies in R&D endeavors, a growing number of hospitals and healthcare institutions are anticipated to fuel the market growth substantially by 2022. Moreover, increasing funding and campaigning offered by non-government institutes is expected to raise the popularity of vaccines, which in turn is supposed to propel demand. Macro indicators such as growing economic development and rising per capita income in developing economies including China, India, and Brazil are also expected to boost the infectious vaccines market growth over the forecast period. However, growing stringent regulatory procedures in production & distribution and increasing costs are projected to hinder the market growth slightly over the forecast period. The lack of awareness and accessibility of a few of the vaccines such as HPV, MMR, and hepatitis E are also anticipated to challenge the market growth by over the forecast period.

A vaccine is a medical product primarily designed to stimulate antibodies against an infectious disease which helps improve the immunity of the target body. There are different types of vaccines available in the industry such as attenuated, inactivated, subunit, toxoid, conjugate, and recombinant vector. Live, attenuated type of vaccine contains active agents that are used to prevent various including measles, yellow fever, mumps, and rubella. Whereas, inactivate type contains micro-organisms that get killed in the chemical reaction, radiation, or heat. These vaccines are primarily used to fight against diseases such as cholera, influenza, polio, bubonic plague, rabies, and hepatitis. The Recombinant vector type is majorly similar to DNA type which uses an attenuated bacterium or virus to fight against diseases such as HIV, measles, and rabies.

The market is segmented by product into the preventive vaccine and the therapeutic vaccine. Preventive vaccines are mainly used to prevent disease rather than the treatment of illness. They majorly work in three prevention levels namely primary, secondary, and tertiary. The main level is used to avoid the occurrence of disease through growing resistance to disease. Secondary level is used to detect and address an existence disease before the appearance of symptoms. The tertiary level is used to reduce the adverse impact of disease after the occurrence of symptoms through treatment and rehabilitation.

The preventive vaccines are primarily used to prevent diseases such as hepatitis A, chickenpox, polio, mumps, measles, influenza (flu), rubella, and hepatitis B. Therapeutic vaccines are primarily used to develop immunity against diseased tissue or cell. The infectious vaccines market is segmented by infectious disease into influenza, pneumococcal, DTP, hepatitis, varicella, polio, rotavirus, cervical cancer, allergy, MMR, and meningococcal. The product is also segmented by the end user into adults and pediatrics.

North America and Europe are expected to account for the highest market share over the next seven years owing to the presence of numerous pharmaceutical companies dedicated to producing various infectious vaccines. The US, the UK, France, Germany are projected to account for major market share primarily due to growing awareness, rising chronic diseases, and increasing government initiatives.

Asia Pacific is anticipated to witness the fastest growth by 2022 owing to rising epidemic diseases, increasing the number of pharmaceutical industry players, and growing disposable income. India, China, and Australia are expected to see the significant market share in the region primarily due to rising immunization initiatives by world health organization (WHO) and growing government action in producing infectious vaccines for diseases such as polio, smallpox, and rotavirus at low cost.

Key players in the sector include CSL Limited (Australia), Bavarian Nordic (Denmark), GlaxoSmithKline plc. (U.K.), Emergent Bio Solutions Inc. (U.S.), MedImmune LLC (U.S.), Johnson and Johnson (U.S.), Novartis AG (Switzerland), Merck and Company (U.S.), Sanofi Pasteur (France) and Pfizer, Inc. (U.S.).